<DOC>
	<DOC>NCT02317159</DOC>
	<brief_summary>This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.</brief_summary>
	<brief_title>Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age≥18； The new diagnosis of CML patients in six months； No proof of extramedullary infiltration of leukemia； ECOG PS score：02； Hepatic and renal functions are normal，Serum bilirubin≤1.5*ULN, serum ALT and AST≤2.5*ULN, serum Cr≤1.5*ULN; Do not receive the treatment of antiCML； Subjects signed informed consent form in line with GCP requirements。 Pregnant or lactating women； Received TKIs any time before； Failure to control systemic infection or multiple organ failure； According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study； Being diagnosed with other malignancies in the prior 12 months； Have a history of neurological or psychiatric disorders, including epilepsy or dementia； Known or suspected allergy to imatinib； BSA≤1.5m2； Using other experimental drugs or participating in other clinical trials in the prior one months。</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>